Distinguished in Troyer Syndrome

Cristiana Bergamini

Head And Neck Medical Oncology Unit, 
Milan, IT 
Distinguished in Troyer Syndrome
Head And Neck Medical Oncology Unit, 
Milan, IT 
OverviewLocationsClinical Research

Overview

Cristiana Bergamini practices in Milan, Italy. Ms. Bergamini is rated as a Distinguished expert by MediFind in the treatment of Troyer Syndrome. Her top areas of expertise are Adenoid Cystic Carcinoma, Salivary Gland Tumors, Troyer Syndrome, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Her clinical research consists of co-authoring 80 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Head And Neck Medical Oncology Unit, Milan, 20133, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: September 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract
Enrollment Status: Completed
Publish Date: August 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

80 Total Publications

Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies.
Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies.
Journal: Immuno-oncology technology
Published: January 22, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bergamini's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile